Enter inventor name

Pradeep Kumar Sharma

This inventor holds 15 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 1 EPO patent. Top assignees: Ariad Pharmaceuticals, Inc., Johnson Matthey Public Limited Company, Takeda Pharmaceutical Company Limited. Active years: 2006-2024.

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 33(Granted Patents)

Location History:

Westford, MA (US) (2006 - 2022)
Cambridge, MA (US) (2024)

Company Filing History:

10 out of 69

Ariad Pharmaceuticals, Inc.

patents

3 out of 853

Johnson Matthey Public Limited Company

patents

2 out of 1,222

Takeda Pharmaceutical Company Limited

patents

Years Active: 2006-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084431 - Pharmaceutical salts of pyrimidine derivatives and method of treating disorders (2024-09-10),

2. 11427605 - Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine (2022-08-30),

3. 11384086 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2022-07-12),

4. 11279705 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2022-03-22),

5. 11192897 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

6. 11192896 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

7. 11192895 - Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2021-12-07),

8. 10934317 - Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine (2021-03-02),

9. 10662197 - Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2020-05-26),

10. 10385078 - Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine (2019-08-20),

11. 10125136 - Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2018-11-13),

12. 9493470 - Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt (2016-11-15),

13. 7161042 - Protected diols for prostaglandin synthesis (2007-01-09),

14. 7141706 - Protected and unprotected triols for prostaglandin synthesis (2006-11-28),

15. 7109371 - Prostaglandin synthesis (2006-09-19),

Title: The Innovations of Pradeep Kumar Sharma: A Remarkable Inventor in Pharmaceutical Development

Introduction

Pradeep Kumar Sharma, based in Westford, MA, has established himself as a prominent figure in the field of pharmaceuticals with a remarkable portfolio of 15 patents. His work primarily focuses on innovative solutions for treating disorders through advanced pharmaceutical compounds.

Latest Patents

Among Pradeep's latest contributions to the pharmaceutical industry are two significant patents. The first patent involves the formulation of pharmaceutical salts of pyrimidine derivatives, aimed at addressing inhibiting activities against mutant epidermal growth factor receptors (EGFR). This groundbreaking disclosure encompasses the processes used for preparing these pyrimidine compounds.

The second patent highlights novel crystalline forms of brigatinib, a medication that plays a critical role in cancer treatment. This patent details pharmaceutical compositions that utilize these crystalline forms and outlines methods for their preparation and application.

Career Highlights

Pradeep has worked with notable companies such as Ariad Pharmaceuticals, Inc. and Johnson Matthey Public Limited Company. During his tenure at these organizations, he has contributed significantly to the development of innovative pharmaceutical solutions, enhancing treatment options for various medical conditions.

Collaborations

Throughout his career, Pradeep has collaborated with esteemed professionals in the field, including Leonard W. Rozamus and Christopher K. Murray. These partnerships have fostered a dynamic exchange of knowledge and expertise, further driving advancements in pharmaceutical innovation.

Conclusion

Pradeep Kumar Sharma continues to be a trailblazer in the pharmaceutical industry, with his extensive patent portfolio showcasing his commitment to innovation and excellence. His contributions have not only advanced the field of pharmaceutical sciences but also provided new hope for patients in need of effective treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]